Protara Therapeutics, Inc. (TARA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Protara Therapeutics reported revenue of $0. Net income was -$57.4M, or -$1.34 per diluted share. Operating activities generated -$56.4M of cash, leaving -$56.5M of free cash flow. At fiscal year end, Protara Therapeutics held $209.5M in total assets against $13.1M in total liabilities, including $49.7M of cash and equivalents.
Open the full interactive Protara Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Protara Therapeutics Key Stats
| Share Price | $2.62 |
|---|---|
| Market Cap | $159.8M |
| 52-Week Range | $2.56 – $7.56 |
| Shares Outstanding | 61.0 million (basic, 2026 Q2) |
Protara Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$34.4M | -$47.5M | -$67.1M | -$43.6M | -$49.2M | -$64.5M |
| Pre-Tax Income | -$34.0M | -$47.3M | -$66.0M | -$40.4M | -$44.6M | $57.4M |
| Income Tax | — | — | — | — | — | $114.8M |
| Net Income | -$34.0M | -$47.3M | -$66.0M | -$40.4M | -$44.6M | -$57.4M |
| Diluted EPS | -$4.70 | -$4.21 | -$5.86 | -$3.57 | -$2.17 | -$1.34 |
Protara Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$13.3M | -$17.3M | -$17.8M | -$21.7M |
| Diluted EPS | -$0.31 | -$0.40 | -$0.31 | -$0.36 |
Protara Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $168.6M | $35.7M | $24.1M | $39.6M | $162.8M | $49.7M |
| Current Assets | $169.4M | $93.1M | $86.1M | $68.7M | $172.2M | $159.5M |
| Total Assets | $203.2M | $172.6M | $113.3M | $79.0M | $181.5M | $209.5M |
| Current Liabilities | $2.9M | $4.3M | $5.7M | $6.1M | $11.0M | $10.9M |
| Total Liabilities | $3.9M | $10.7M | $11.2M | $10.6M | $14.3M | $13.1M |
| Shareholders' Equity | $199.2M | $161.9M | $102.1M | $68.3M | $167.1M | $196.4M |
Protara Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$23.4M | -$34.5M | -$26.5M | -$37.6M | -$35.8M | -$56.4M |
| Cash From Investing | $2.8M | -$98.2M | $14.9M | $53.1M | $19.2M | -$139.5M |
| Cash From Financing | $189.4M | -$228,000 | -$90,000 | -$91,000 | $139.9M | $82.7M |
| Free Cash Flow | -$24.3M | -$35.1M | -$26.6M | -$37.6M | -$35.9M | -$56.5M |
Figures from Protara Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Protara Therapeutics financials page for every line item.
Protara Therapeutics Company Profile
| Ticker | TARA |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | New York, New York |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001359931 |
Frequently Asked Questions
What was Protara Therapeutics' revenue in fiscal 2025?
Protara Therapeutics (TARA) reported revenue of $0 for fiscal 2025.
What is Protara Therapeutics' annual revenue history?
Protara Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Protara Therapeutics' net income in fiscal 2025?
Protara Therapeutics reported net income of -$57.4M for fiscal 2025.
What was Protara Therapeutics' earnings per share (EPS) in fiscal 2025?
Protara Therapeutics' diluted EPS was -$1.34 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Protara Therapeutics generate in fiscal 2025?
Protara Therapeutics generated -$56.5M of free cash flow in fiscal 2025.
What was Protara Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Protara Therapeutics reported revenue of $0.
How many shares of Protara Therapeutics are outstanding?
Protara Therapeutics reported a weighted average of 61.0 million basic shares outstanding in 2026 Q2.
What is Protara Therapeutics' market cap?
Based on its latest closing price, Protara Therapeutics (TARA) has a market capitalization of about $159.8M.
When does Protara Therapeutics' fiscal year end?
Protara Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Protara Therapeutics headquartered?
Protara Therapeutics lists its business address in New York, New York in its SEC filings.
Protara Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →